

14 Mar 2019 | Analysis

QUOTED. March 14, 2019. Mika Wang.

by

The current annual global manufacturing market for liquid biopsy is roughly \$170m – representing a 90% yearly increase since 2015 – and it's expected to reach about \$1bn by 2023. See what DeciBio Consulting's Mika Wang said about it here.

"By indication, we expect lung, breast, prostate, colorectal and pan-cancer testing to drive growth over the next several years. Some of the less common cancers in our global liquid biopsy database include nasopharyngeal carcinoma, hepatocellular carcinoma and brain and spinal cord tumors (gliomas)." –Mika Wang, head of product strategy, DeciBio Consulting LLC

- Find out more: [Liquid Biopsy: Ready For Prime Time?](#)

[Click here](#) for a free trial of *Medtech Insight*